Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arno Therapeutics, Inc. (OTC: ARNI).

Full DD Report for ARNI

You must become a subscriber to view this report.


Recent News from (OTC: ARNI)

Arno Therapeutics Announces Plans to Dissolve
Arno Therapeutics, Inc. (ARNI), a biopharmaceutical company, today announced that it has sold substantially all of its remaining assets and will be dissolving by the end of this year. Its last remaining assets were the rights to Onapristone, which it recently sold to Context Biopharma, Inc. ...
Source: Business Wire
Date: December, 22 2017 09:10

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-17N/A0.00275N/AN/A0
2018-12-14N/A0.00275N/AN/A0
2018-12-13N/A0.00275N/AN/A0
2018-12-120.002750.002750.002750.00275330
2018-12-110.00370.00320.00370.002713,100

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1113,00013,10099.2366Short
2018-10-1942,00062,00067.7419Short
2018-09-281,0001,000100.0000Short
2018-08-2325,00035,00071.4286Short
2018-07-05360,200372,70096.6461Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARNI.


About Arno Therapeutics, Inc. (OTC: ARNI)

Logo for Arno Therapeutics, Inc. (OTC: ARNI)

Arno is a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics. The company has exclusive worldwide rights to three innovative clinical stage compounds with unique mechanisms of action that have the potential to be first in class products for the treatment of various forms of cancer, including both hematologic malignancies and solid tumors, and other life threatening diseases. The lead compound, onapristone, is an oral, anti progestin currently in a Phase I/II clinical trial for patients with castration resistant prostate cancer.

 

Contact Information

 

 

Current Management

  • Alexander Zukiwski / CEO, Chief Med. Officer
  • Lester Szymanik / Director, Fin.

Current Share Structure

  • Market Cap: $128,309 - 03/09/2018
  • Authorized: 500,000,000 - 09/30/2016
  • Issue and Outstanding: 49,349,749 - 11/09/2016
  • Float: 14,000,000 - 09/30/2016

 


Recent Filings from (OTC: ARNI)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 03 2018

 

 


Daily Technical Chart for (OTC: ARNI)

Daily Technical Chart for (OTC: ARNI)


Stay tuned for daily updates and more on (OTC: ARNI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ARNI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARNI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ARNI and does not buy, sell, or trade any shares of ARNI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/